Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
RAPT Therapeutics, Inc. RAPT
$18.44
-$0.5 (-2.69%)
На 18:02, 12 мая 2023
+128.85%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
679793303.00000000
-
week52high
32.45
-
week52low
10.35
-
Revenue
1527000
-
P/E TTM
-8
-
Beta
0.36921200
-
EPS
-2.60000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 11 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 23 июн 2022 г. |
| Piper Sandler | Overweight | Overweight | 12 мая 2022 г. |
| Wells Fargo | Overweight | Overweight | 11 мар 2022 г. |
| Capital One | Overweight | 21 сент 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 14 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 11 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 04 янв 2023 г. |
| Guggenheim | Buy | 04 янв 2023 г. | |
| Goldman Sachs | Buy | 01 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wong Brian Russell | A | 250000 | 250000 | 31 янв 2023 г. |
| Young Rodney KB | A | 68000 | 68000 | 31 янв 2023 г. |
| HO WILLIAM | A | 56000 | 56000 | 31 янв 2023 г. |
| Brockstedt Dirk G. | A | 56000 | 56000 | 31 янв 2023 г. |
| HO WILLIAM | D | 30072 | 5000 | 24 янв 2023 г. |
| HO WILLIAM | D | 35072 | 5000 | 19 янв 2023 г. |
| HO WILLIAM | D | 4601 | 1380 | 12 янв 2023 г. |
| HO WILLIAM | D | 0 | 1042 | 12 янв 2023 г. |
| HO WILLIAM | A | 40072 | 1380 | 12 янв 2023 г. |
| HO WILLIAM | A | 38692 | 1042 | 12 янв 2023 г. |
Новостная лента
Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)
Zacks Investment Research
25 янв 2023 г. в 10:33
Rapt Therapeutics (RAPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 08:00
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. Pacific Time.
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
GlobeNewsWire
30 ноя 2022 г. в 19:05
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that its abstract from its ongoing Phase 1/2 study of FLX475 as monotherapy and in combination with pembrolizumab in cancer patients has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress taking place December 7-9, 2022 in Geneva, Switzerland. The presentation will include data from checkpoint inhibitor-naïve NSCLC patients treated with the combination of FLX475 plus pembrolizumab including their PD-L1 status, and patients with EBV-positive NK/T cell lymphoma treated with FLX475 monotherapy.
Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick
Zacks Investment Research
22 ноя 2022 г. в 09:47
RAPT Therapeutics (RAPT) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
23 сент 2022 г. в 13:32
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.